Novartis Aktie - NVS

Professionelle Tools für Privatanleger.

Premium

Current Price

103,24

Gebot

Fragen

Volumen

7.377

0,00 Tagesbereich 0,00

92,35 52-Wochen-Bereich 120,92

Marktkapitalisierung

211,026B

Handelsende

103,09

Handelsbeginn

Letzte Trade

100

103.24

(formt)

Letzter Handelszeitpunkt

12:10:11

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.109.557

Ausgegebene Aktien

2.044.033.986

Dividendenrendite

Kurs-Gewinn-Verhältnis

13,52

Gewinn pro Aktie (EPS)

7,27

Erlöse

54,11B

Nettogewinn

14,85B

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, ca... Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.novartis.com

Hauptsitz

Basel, Che

Gegründet

Novartis AG is listed in the Pharmaceutical Preparations sector of the New York Börse with ticker NVS. The last closing price for Novartis was US$103,09. Over the last year, Novartis shares have traded in a share price range of US$ 92,35 to US$ 120,92.

Novartis currently has 2.044.033.986 shares in issue. The market capitalisation of Novartis is US$210,72 billion. Novartis has a price to earnings ratio (PE ratio) of 13.52.

Gesamtfluss

Bärisch

Nettoprämie

-6k

Calls / Puts

100,00%

Käuf. / Verkä.

100,00%

OTM / ITM

0,00%

Sweeps

0,00%

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate PR Newswire BOSTON, Nov. 18, 2024 Ratio to receive upfront, and potential milestones...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR Newswire EAST HANOVER, N.J., Oct. 18, 2024 If approved...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that...

Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget

Novartis si assicura i diritti esclusivi globali alla tecnologia di microglassification di Lindy Biosciences in diversi target biologici La collaborazione mira a consentire trattamenti...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.99	-0.949822507915	104.23	104.68	102.4	1307045	103.20184064	DR
4	-10.84	-9.50210378682	114.08	115.765	102.4	1367231	107.61398053	DR
12	-16.85	-14.0311433092	120.09	120.92	102.4	1109557	112.55516718	DR
26	0.46	0.44755789064	102.78	120.92	98.913	1190816	110.16507627	DR
52	7.11	7.3962342661	96.13	120.92	92.35	1345360	104.4495539	DR
156	21.52	26.3338228096	81.72	120.92	74.09	1871333	92.45877805	DR
260	13.16	14.6092362345	90.08	120.92	69.1	1925321	90.43100867	DR

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
PSBDPalmer Square Capital BDC Inc	US$ 22,99 (44,32%)	1
ACRACRES Commercial Realty Corporation	US$ 23,99 (43,31%)	2
SNDASonida Senior Living	US$ 33,00 (38,83%)	3
SDHYPGIM Short Duration High Yield Opportunities Fund	US$ 21,95 (32,63%)	2
SNOWSnowflake Inc	US$ 157,60 (22,06%)	269,11k
AVNSAvanos Medical Inc	US$ 11,01 (-38,39%)	105
SMPStandard Motor Products Inc	US$ 20,00 (-36,67%)	102
CBANColony Bankcorp Inc	US$ 11,12 (-34,47%)	4
SDHCSmith Douglas Homes Corp	US$ 21,00 (-32,78%)	108
WSWorthington Steel Inc	US$ 35,22 (-19,86%)	208
SNOWSnowflake Inc	US$ 157,60 (22,06%)	269,11k
NIONIO Inc	US$ 4,57 (-1,72%)	258,06k
PLTRPalantir Technologies Inc	US$ 61,74 (-0,61%)	228,37k
IONQIonQ Inc	US$ 28,20 (-2,29%)	222,76k
ZETAZeta Global Holdings Corp	US$ 23,45 (1,47%)	183,36k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novartis AG (NVS) Börsenkurse

Novartis AG (NVS)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Novartis AG

Option-Flow Novartis (NVS)

Gesamtfluss

Bärisch

Nettoprämie

-6k

Calls / Puts

100,00%

Käuf. / Verkä.

100,00%

OTM / ITM

0,00%

Sweeps

0,00%

NVS Neueste Nachrichten

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen